Correspondence
Sustained and expedited resolution of diabetic papillopathy with combined PRP and bevacizumab
Diabetic papillopathy (DP) is a rare condition that occurs in 1.4% of patients with type I and II diabetes.1 It is unilateral in 50% of cases and associated with diabetic retinopathy progression.1 Although it is traditionally a self-limited disease with spontaneous resolution within 3 to 4 months,2,3 it may precede the development of nonarteritic anterior ischemic optic neuropathy, which can result in permanent vision loss. It is controversial whether DP is actually a mild reversible form of nonarteritic anterior ischemic optic neuropathy.Unilateral manifestation of autoimmune retinopathy
Autoimmune retinopathy (AIR) encompasses a spectrum of rare autoimmune diseases, including cancer-associated retinopathy and nonparaneoplastic-associated retinopathy, which primarily affect retinal photoreceptor function, and melanoma-associated retinopathy (MAR), which primarily affects bipolar cell function. Clinical features include panretinal degeneration with no or little pigment deposition, progressive visual field deficits, and photopsias with or without a history of carcinoma or melanoma at the time of ocular presentation.
